Pharmaceutical company Organon (NYSE: OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on year to $1.51 billion. The company’s full-year revenue guidance of $6.2 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $0.63 per share was 13.3% below analysts’ consensus estimates.

Is now the time to buy OGN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Organon's fourth quarter was met with a negative market reaction as operational challenges and shifting demand patterns weighed on results. Management pointed to continued pricing pressure, loss of exclusivity for key drugs like Atozet, and policy-related headwinds for Nexplanon in the U.S. as major drivers of the year-on-year revenue decline. Interim CEO Joe Morrissey emphasized that biosimilars, particularly Hadlima, and new product launches provided some offset, but cost containment efforts and product mix shifts could not fully mitigate gross margin compression. CFO Matthew Walsh described the gross margin decline as “primarily driven by pricing pressure and unfavorable product mix.”

Looking ahead, Organon's guidance for 2026 reflects both caution and targeted investment, with management expecting revenue and adjusted EBITDA to remain roughly flat. The company is focusing on ex-U.S. growth for Nexplanon, biosimilar launches, and disciplined expense management to counter persistent pressure in established brands and competitive fertility markets. Walsh indicated that operating cost reductions will continue, but acknowledged, “it’s essential that we continue to rightsize the operating expense footprint of the company in light of what’s happening in terms of our gross margins being compressed.” Management also highlighted the importance of successful recertification for the Nexplanon REMS program and the gradual stabilization of established brands as key elements of their strategy.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to pricing and policy headwinds in core franchises and the impact of cost control measures, while highlighting progress in biosimilars and selective product launches.

• Nexplanon’s U.S. policy headwinds: Nexplanon sales were pressured by policy-related access restrictions at key clinics and a shift in purchasing patterns among smaller commercial clinics. Management expects these challenges to persist in 2026, but points to ex-U.S. markets, particularly Latin America, as growth opportunities.

• Biosimilars momentum and risk: Biosimilars, led by Hadlima, grew significantly due to strategic pricing and expansion into new markets like Canada and Puerto Rico. Recent launches, such as denosumab biosimilars and Tofidence, contributed incremental growth, but management described the competitive U.S. biosimilars landscape as likely to yield only incremental gains rather than transformative margin expansion.

• Cost savings offsetting margin erosion: Organon achieved over $200 million in annual cost savings, primarily through reductions in administrative and R&D spending. These efforts helped keep non-GAAP EBITDA margins stable despite a 150 basis point drop in gross margin, but the company continues to balance efficiency initiatives with targeted investments in growth drivers like Vtama.

• Divestiture and capital allocation changes: The divestiture of the Jada system provided $390 million in proceeds, which, along with a lower dividend payout, is being directed toward debt reduction. Management stressed that these actions reflect a commitment to improving the company’s financial flexibility for future opportunities.

• Established brands pressure and stabilization: The established brands portfolio faced a reset due to respiratory segment declines and loss of exclusivity events, but contributions from Emgality and Vtama, along with reduced exposure to pricing erosion in Japan and Europe, are expected to support more stable performance in the coming year.

Drivers of Future Performance

Organon’s 2026 outlook emphasizes expense discipline, ex-U.S. product growth, and careful management of policy and pricing headwinds.

• Expense discipline continues: Management is pursuing further operating cost reductions in 2026 to offset ongoing gross margin pressure, particularly from higher costs of goods sold related to foreign exchange impacts and inventory adjustments. Efforts are focused on administrative efficiencies without sacrificing targeted investments in key growth areas.

• Ex-U.S. Nexplanon and biosimilars growth: With U.S. Nexplanon volumes constrained by policy and reinsertion headwinds, management expects international expansion—especially in Latin America—and new biosimilar launches to drive modest volume growth. However, the company acknowledges that competitive pressures in fertility and established brand portfolios may dampen overall momentum.

• REMS and regulatory transitions: Successful implementation of the updated Nexplanon REMS (Risk Evaluation and Mitigation Strategy) program is a priority, as management believes streamlined prescriber recertification will minimize volume disruption. The team also anticipates that stabilization in established brand pricing, particularly in Japan and Europe, will help mitigate future revenue volatility.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team will be tracking (1) execution of further cost reduction initiatives and their impact on margin stability, (2) volume and pricing trends for Nexplanon outside the U.S. as well as biosimilar adoption in new markets, and (3) stabilization in the established brands portfolio, especially in respiratory and fertility segments. Developments in the Nexplanon REMS program and debt reduction progress will also be important indicators.

Organon currently trades at $7.10, down from $7.69 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.